GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody is a research paper published in PLoS ONE (2020). On theSindex it has a DataRank of 0. It has been cited 7 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: F30CA196199
National Institute of Neurological Disorders and Stroke
Grant: R01NS08541
National Institute of Neurological Disorders and Stroke
Grant: U01NS090284
National Cancer Institute
Grant: R01CA177476
National Institute of Neurological Disorders and Stroke
Grant: R01NS086943
National Institute of Neurological Disorders and Stroke
Grant: R01NS099463
NIGMS NIH HHS
Grant: T32 GM145449
National Institutes of Health
Grant: 5R01CA177476-03
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells
National Institutes of Health
Grant: 5F30CA196199-02
Systemic EGFRvIII-targeted bispecific antibody as immunotherapy for glioblastoma
National Institutes of Health
Grant: 5U01NS090284-02
Human EGFRvIII-specific BiTE for the treatment of Glioblastoma
National Institutes of Health
Grant: 5R01NS086943-04
Brain Tumor Targeting Using Tumor-Specific Neuroimmunology
National Institutes of Health
Grant: 1R01DA008541-01
COGNITIVE BEHAVIOR THERAPY OF DEPRESSED COCAINE ADDICTS
National Institutes of Health
Grant: 1R01NS099463-01
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy
FWCI
0.30
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals